Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Specialty pharmaceutical company Warner Chilcott
So what: Despite receiving a decent boost from the products acquired in its Procter & Gamble
Now what: Even with today's miss, management said the overall integration of P&G's portfolio is going rather smoothly. Generic competition from the likes of Teva
Interested in more info on Warner Chilcott? Add it to your watchlist by clicking here.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Procter & Gamble is a Motley Fool Income Investor pick. The Fool owns shares of P&G and Teva. Try any of our Foolish newsletter services free for 30 days.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.